NO clamp

PreclinicalSmall molecule

UUniversity of Edinburgh

NO clamp is one of 4 small molecule programs targeting Takotsubo cardiomyopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Takotsubo CardiomyopathyActive, not recruiting

Takotsubo CardiomyopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Takotsubo Cardiomyopathy

#DrugCompanyPhaseTrials

Neoral

Zebeta

1 3

Farxiga

AstraZeneca

Preclinical

1 4

NO clamp

UUniversity of Edinburgh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

N/ARecruiting

Takotsubo Cardiomyopathy

NCT07491718

Clinical

Trials by Indication[1]

Takotsubo cardiomyopathy1 trial

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Recruiting·UUniversity of Edinburgh·N/A·NCT07491718·100 enrolled

ART1 trial

Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 3)

Completed·UUniversity of Edinburgh·N/A·NCT01096706·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NO clamp. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NO clamp compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NO clamp. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Edinburgh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Edinburgh

NO clamp

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Takotsubo cardiomyopathy1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News